Georges Gemayel - Orphazyme Chairman of the Board

ORPHA Stock  DKK 915.00  9.90  1.07%   

Chairman

Dr. Georges Gemayel, Ph.D. serves as Chairman of the Board at ORPHAZYME AS. Currently, he is Chairman of the Board of Enterome and Oxthera. He is also Director at Dimension Therapeutics, Momenta, Supernus and Raptor Pharmaceuticals. Previously, he was General Manager at Roche Portugal Vice Presidentat Specialty Care Roche US Executive Vice President at Genzyme CEO of Altus Director of Adolor, NPS, Epitherapeutics and Prosensa Executive Chairman at FoldRx and Syndexa.
Age 59
Professional MarksPh.D
Phone45 39 17 82 72
Webhttps://www.orphazyme.com

Orphazyme Management Efficiency

The company has return on total asset (ROA) of (1.334) % which means that it has lost $1.334 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (4.8658) %, meaning that it generated substantial loss on money invested by shareholders. Orphazyme's management efficiency ratios could be used to measure how well Orphazyme manages its routine affairs as well as how well it operates its assets and liabilities.
Orphazyme AS has accumulated 2.48 M in total debt with debt to equity ratio (D/E) of 0.11, which may suggest the company is not taking enough advantage from borrowing. Orphazyme AS has a current ratio of 4.61, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Orphazyme until it has trouble settling it off, either with new capital or with free cash flow. So, Orphazyme's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Orphazyme AS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Orphazyme to invest in growth at high rates of return. When we think about Orphazyme's use of debt, we should always consider it together with cash and equity.
Orphazyme AS, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. Orphazyme is traded on Copenhagen Stock Exchange in Denmark. Orphazyme AS (ORPHA) is traded on Copenhagen Exchange in Denmark and employs 2 people.

Management Performance

Orphazyme AS Leadership Team

Elected by the shareholders, the Orphazyme's board of directors comprises two types of representatives: Orphazyme inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orphazyme. The board's role is to monitor Orphazyme's management team and ensure that shareholders' interests are well served. Orphazyme's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orphazyme's outside directors are responsible for providing unbiased perspectives on the board's policies.
Remi Droller, Director
Anders Hedegaard, Director
MBA MSc, CFO CEO
Georges Gemayel, Chairman of the Board
Jennifer McCann, I US
Bo Hansen, Deputy Chairman of the Board
Anders Vadsholt, Interim Chief Executive Officer, Chief Financial Officer
Thomas Blaettler, Chief Medical Officer
Catherine Moukheibir, Director
Sten Verland, Director
Kim Stratton, Chief Executive Officer
Martin Bonde, Director
Thomas Jensen, Chief Scientific Officer
Martijn Kleijwegt, Director

Orphazyme Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Orphazyme a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Orphazyme

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Orphazyme position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Orphazyme will appreciate offsetting losses from the drop in the long position's value.

Moving together with Orphazyme Stock

  0.75DANT DantaxPairCorr

Moving against Orphazyme Stock

  0.58SHAPE Shape Robotics ASPairCorr
  0.48GMAB Genmab ASPairCorr
  0.4STENO Stenocare ASPairCorr
The ability to find closely correlated positions to Orphazyme could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Orphazyme when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Orphazyme - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Orphazyme AS to buy it.
The correlation of Orphazyme is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Orphazyme moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Orphazyme AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Orphazyme can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Orphazyme Stock

Orphazyme financial ratios help investors to determine whether Orphazyme Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Orphazyme with respect to the benefits of owning Orphazyme security.